<DOC>
	<DOCNO>NCT01190228</DOCNO>
	<brief_summary>The aim study investigate memory immune response yearly persistence immunity Japanese Encephalitis ( JE ) vaccination new Japanese Encephalitis Chimeric Virus ( JE-CV ) participants previously vaccinate JE-CV . Objectives : - To describe JE immune status , JE-CV booster dose subject previously vaccinate JE-CV - To describe immune status , immune response follow JE-CV vaccination JE-na√Øve control subject . - To describe safety ( term solicit unsolicited adverse event ) single dose JE-CV 6 month last vaccination . - To describe related serious adverse event ( SAEs ) relate death 6 month 5 year vaccination JE-CV-primed subject .</brief_summary>
	<brief_title>Study Japanese Encephalitis Chimeric Virus Vaccine ( JE-CV ) Children Previously Immunized With JE-CV</brief_title>
	<detailed_description>Study participant previously immunize Japanese Encephalitis Chimeric Virus ( JE-CV ) vaccine receive single dose new JE-CV follow 5 year immunogenicity . The control ( JE-CV naive ) participant receive either one dose JE-CV one dose varicella vaccine . All participant monitor safety 6 month post vaccination .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>All Participants Aged 36 42 month day inclusion Provision Informed Consent Form sign least one parent legally acceptable representative . Subject parent/legally acceptable representative guardian able attend schedule visit comply trial procedure In good general health , base medical history physical examination For Japanese Encephalitis Chimeric Virus ( JECV ) vaccine prim group Subject vaccinate JECV JEC02 trial ( NCT00735644 ) History central nervous system disorder disease , include seizure febrile seizure Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Chronic illness underlie illness ( cardiovascular , kidney , liver hematological disease development abnormality ) , opinion investigator , stage might interfere trial conduct completion For Japanese Encephalitis Chimeric Virus ( JECV ) prim participant Receipt Japanese Encephalitis ( JE ) vaccine JECV JEC02 trial ( NCT00735644 ) since end JEC02 trial For JECV naive participant Previous vaccination flavivirus disease include JE History flavivirus infection either base clinical suspicion laboratory proven Previous vaccination varicella Previous vaccination JECV JEC02 study History varicella , confirm either clinically , serologically , microbiologically Known systemic hypersensitivity anaphylactic/anaphylactoid reaction neomycin . Known history thrombocytopenia idiopathic thrombocytopenic purpura .</criteria>
	<gender>All</gender>
	<minimum_age>36 Months</minimum_age>
	<maximum_age>42 Months</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Japanese Encephalitis</keyword>
	<keyword>Japanese encephalitis chimeric virus vaccine</keyword>
	<keyword>Varicella</keyword>
	<keyword>Varicella vaccine</keyword>
</DOC>